Cemiplimab is an cemiplimab anti-PD-1 immune checkpoint inhibitor used in oncology, with its primary mechanism being blockade of PD-1-mediated immune suppression to enhance antitumor immunity. It is being studied in metastatic non-small cell lung cancer, including the TOP2201 phase II setting and first-line combination strategies with chemotherapy, and it has also been incorporated into cervical cancer treatment discussions with reported survival benefit. Recent literature highlights an ongoing single-arm, multi-center phase II study of cemiplimab plus alirocumab in advanced immuno-refractory metastatic NSCLC, as well as a cost-effectiveness analysis comparing pembrolizumab plus chemotherapy versus cemiplimab plus chemotherapy in first-line metastatic NSCLC. Overall, the evidence base positions cemiplimab as a clinically relevant PD-1 inhibitor across both lung and cervical cancer contexts, with combination regimens and comparative effectiveness now being actively evaluated. The cited studies emphasize its role in advanced disease management and in treatment optimization rather than as a standalone cytotoxic agent.
Metastatic non-small cell lung cancer
- Cemiplimab is being evaluated as part of an ongoing single-arm phase II study with alirocumab in advanced immuno-refractory metastatic NSCLC. (PMID:41940540)
- The study context specifically involves alirocumab combined with cemiplimab in metastatic NSCLC. (PMID:41940540)
- Cemiplimab is also being assessed as part of first-line treatment strategies combined with chemotherapy for metastatic non-small cell lung cancer. (PMID:41861397)
- A US payer-perspective cost-effectiveness analysis compared pembrolizumab plus chemotherapy versus cemiplimab plus chemotherapy in first-line metastatic NSCLC. (PMID:41861397)
Cervical cancer
- Cemiplimab was included in cervical cancer treatment discussions as an immune checkpoint inhibitor associated with improved survival. (PMID:41958269)
- The review frames cemiplimab within the broader immunotherapy-driven shift in the cervical cancer therapeutic landscape. (PMID:41958269)
- Its role is presented as part of a treatment strategy rather than as a monotherapy-specific finding. (PMID:41958269)